9 Evidence-Based Health Benefits of Chestnuts
Chestnuts are the edible nuts of trees and shrubs that belong to the Castanea genus. They have a delicious, mildly sweet taste and are incredibly versatile. You can incorporate them into a variety of dishes like stuffings, salads, and soups.
There are many different types of chestnuts, and they share similar qualities. The most common types include the American chestnut, Chinese chestnut, Japanese or Korean chestnut, and European chestnut.
It's worth noting that they're not related to the water chestnut (Eleocharis dulcis), a type of aquatic vegetable popular in Asian cuisine.
Here are nine intriguing health benefits of chestnuts.
1. Packed with nutrients
Despite their small size, chestnuts are packed with a variety of nutrients.
A 10-kernel (84-gram) serving of roasted chestnuts provides the following:
Calories: 206
Protein: 2.7 grams
Fat: 1.9 grams
Carbs: 44.5 grams
Fiber: 4.3 grams, 15% of the daily value (DV)
Copper: 47% of the DV
Manganese: 43% of the DV
Vitamin B6: 25% of the DV
Vitamin C: 24% of the DV
Thiamine: 17% of the DV
Folate: 15% of the DV
Riboflavin: 11% of the DV
Potassium: 11% of the DV
Chestnuts are also a decent source of several other vitamins and minerals, including vitamins K, B5, and B3, as well as phosphorus and magnesium.
Compared with most other nuts, chestnuts contain fewer calories because they are low in fat. They are also higher in carbs than most nuts and contain a good amount of fiber, providing 15% of your daily needs in one serving.
2. Great source of antioxidants
Chestnuts contain a wide variety of antioxidants, which are important for your health.
These antioxidants include:
vitamin C
gallic acid
ellagic acid
tannins
alkaloids
various polyphenols
lutein
zeaxanthin
Lutein and zeaxanthin accumulate in the retinas of your eyes and protect them against damage from blue light.
Antioxidants are compounds that help protect your cells against damage from unstable molecules called free radicals.
High levels of free radicals may cause a state called oxidative stress. This can increase the risk of chronic diseases, such as heart disease, diabetes, and cancers.
In addition, studies have shown that various antioxidants found in chestnuts, such as gallic and ellagic acid, may help lower the risk of heart disease, reduce insulin resistance, and suppress the growth and spread of tumors.
3. May aid heart health
Chestnuts are a good source of nutrients that are great for your heart.
For starters, they contain antioxidants, such as gallic and ellagic acid. Studies have found that these antioxidants may help protect the heart against oxidative stress, a condition that may raise the risk of strokes and heart disease.
Chestnuts are also a good source of potassium, providing 11% of your daily needs. Potassium is important for a healthy heart and helps regulate your blood pressure.
In addition, research has found that consuming a potassium-rich diet may lower the risk of heart disease and strokes.
4. High in fiber
Chestnuts are a good source of fiber, which has many health benefits.
For one, fiber helps add bulk to your stools, which makes them easier to pass.
In addition, the fiber in your diet reaches your colon largely undigested, where it acts as a prebiotic. This means the fiber becomes a source of nourishment for the healthy bacteria in your gut that ferment fiber.
When gut bacteria ferment fiber, they produce various beneficial compounds, including short-chain fatty acids.
These short-chain fatty acids offer numerous benefits. Studies have shown they may aid gut health, reduce inflammation, and improve blood sugar control.
Lastly, because fiber passes through your body largely undigested, it contributes to feelings of fullness without adding calories to your diet. This may help with weight management.
5. May improve blood sugar control
Maintaining your blood sugar at a healthy level is important for your health, but especially important if you have prediabetes or diabetes.
Prolonged high blood sugar levels can raise the risk of health complications like damage to the blood vessels and organs.
Chestnuts have several intriguing properties that may aid blood sugar control.
Despite being higher in carbs than most nuts, chestnuts are a good source of fiber that can help prevent blood sugar spikes.
In addition, research has shown that chestnut antioxidants, such as gallic and ellagic acid, help manage blood sugar levels and may improve insulin sensitivity, making your cells more responsive to insulin.
However, chestnuts are still considered a higher carb nut. While eating a small to moderate quantity of chestnuts may offer these benefits, consuming too many chestnuts frequently may counter these health benefits.
6. May aid weight loss
Chestnuts have several properties that may aid weight loss.
The high proportion of fiber they contain can help you stay fuller for longer. This is because fiber can help slow down the time it takes for food to empty from the stomach into the intestines.
In addition, research has shown that high fiber intake can increase the production of hormones that help curb your appetite, such as peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), while suppressing the hunger hormone ghrelin.
Furthermore, chestnuts contain fewer calories per gram than most other nuts. This is because they are low in fat, which is the most calorie-dense nutrient.
If you are looking to lose weight, you will need to create a calorie deficit to do so. Eating chestnuts may help you do this while also helping you feel full.
Interestingly, one 2020 animal study found that consuming chestnuts may help reduce cholesterol and belly fat. However, more research is needed to investigate these potential effects.
7. May lower inflammation
Inflammation is a natural process that helps the body heal and fight infections.
In some situations, inflammation may persist at a low level. This is known as chronic inflammation and is linked to numerous chronic conditions, such as heart disease, diabetes, and cancers.
The antioxidants chestnuts contain, such as vitamin C, gallic acid, ellagic acid, and various polyphenols, may help reduce inflammation. They neutralize free radicals, which are key drivers of chronic inflammation.
In addition, test-tube and animal studies have shown that chestnut antioxidants, such as tannins and flavonoids, can help suppress inflammatory signals like NF-κB and MAPK.
8. Potential anti-tumor properties
Lab research suggests that the antioxidants found in chestnuts may help suppress the growth and spread of cancer cells and stimulate cancer cell death.
Studies show that extracts from chestnuts suppressed the growth and spread of various types of cancer cells, such as prostate, breast, and colon cancers.
Research on chestnut antioxidants has found that they may also suppress the spread of tumor cells and stimulate tumor cell death. In particular, ellagic acid targets the PI3K signaling pathway, which regulates cell growth and survival.
However, more research is needed to understand how the compounds found in chestnuts may affect cancer cells in people.
9. Delicious and easy to add to your diet
Not only are chestnuts healthy, but they are also delicious and easy to add to your diet. They have a mildly sweet flavor and soft yet firm texture.
Although you can eat chestnuts raw, they are high in tannins, which may cause digestive issues or other complications in people sensitive to tannins.
They are easy to prepare. You can roast them in the oven on a baking sheet for 20 to 30 minutes at 400°F (200°C). Make sure to pierce the nuts' skin before roasting to prevent them from exploding in the oven.
Alternatively, you can boil the chestnuts in a pot of water. Bring the pot to boil and then lower the heat to allow them to simmer for approximately 30 minutes. Again, make sure to pierce the skin of the chestnuts beforehand.
Once the chestnuts are cooked, their skin is easy to remove so you can enjoy them as a delicious snack. They are also incredibly versatile and you can incorporate them into salads, stuffings, soups, and desserts, such as tarts and pies.
Takeaway
Chestnuts are a popular nut that people enjoy around the world.
They are a good source of fiber, vitamin C, copper, B vitamins, manganese, and various antioxidants, which are linked to numerous health benefits.
Chestnuts and their nutrients may help improve heart health, blood sugar control, weight loss, inflammation, and digestive health, and may have potential anticancer properties.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
These 5 Tips Will Help You Burn More Fat During Every Walk. Here's How To Walk Smarter, Not Longer.
Apart from being a low-impact exercise that you can do literally anytime, anywhere, walking can be just as great (if not better!) at spurring weight loss compared to high-intensity boot camps and other balls-to-the-wall workouts, says personal trainer Chris Freytag, CPT, founder of Get Healthy U TV, and board member of the American Council of Exercise. In fact, one Risk Analysis study found that women who go for regular brisk walks tend to have lower body mass indexes than those who opt for other forms of exercise. Plus, the other health benefits of walking are pretty major: the activity can help with brain health, longevity, and more. If weight loss is your goal, try amping up your walk with these expert-approved tips: 1. Walk fast enough to make talking hard 'Since so many people don't have time for two-hour walks every day, making the most of the time you have is key,' Freytag says. 'By adding some speed and intensity to your walks, you can up your calorie burn, improve your lung capacity, and absolutely take off some pounds.' To make sure your intensity is where it needs to be, focus on your breathing. If you're walking along at a fat-burning rate, you should only be able to get out a few words at a time without taking a breath, she says. Ready to make walking a regular part of your routine? Get the WH+ Exclusive 4-Week Walking Plan that burns fat and builds muscle at the same time. 2. Add some slower intervals Still, you don't need to race through your entire workout to help with weight loss. In fact, Ohio State University research shows that altering your walking speed burns up to 20 percent more calories than walking at a steady pace. Think of it sort of like driving on the highway without cruise control. By regularly letting on and off of the gas and break pedals, you burn through way more gas—a.k.a. calories, according to researchers. You don't have to follow a structured speed plan, though. (But if you prefer a plan, we got you.) Just try walking as fast as you can to that next tree, then slow down. Then, speed back up when you hit the fire hydrant. You get the idea. 3. Unless you walk in the morning, skip pre-workout snacks While exercising on empty is never a good weight-loss strategy, you don't need to pump calories or carbs before walking workouts the way you do before intense boot camps or 10-mile runs, says Tori Holthaus, RDN, founder of YES! Nutrition. That's because walking probably won't deplete your body's stored carbs as quickly as higher-intensity exercises. Simply eating balanced meals and snacks containing whole carbs, lean protein, and healthy fat throughout the day will provide you with all of the energy you need to power through the vast majority of your walks, she says. If, however, you like to go on walks first thing in the morning, eat something before you head out the door, since you probably haven't eaten in the last eight hours. You can also mix some protein powder into your water bottle to help keep your blood sugar levels stabilized, says San Diego bariatric surgeon Julie Ellner, MD. 4. Refuel after walking 60 minutes or more Though it's not a huge deal if you don't eat after a quick 30-minute walk, it's very important to refuel after hitting the road for an hour or more. 'In this case, your glycogen stores will be depleted, and you need to replenish those stores to feed your muscles,' Freytag says. Opt for a small, post-walk snack that contains a roughly three-to-one ratio of carbs to protein. Some solid choices include a banana with nut butter, piece of whole-grain avocado toast, or glass of chocolate milk. 5. Incorporate resistance training Walking is a great way to lose weight, but to make sure that you aren't losing muscle mass, you need to integrate strength training into your routine, Ellner says. Stop every 10 minutes during your walks to perform a few sets of pushups, lunges, squats, or other bodyweight exercises, says Freytag. Once you finish off your last rep, keep walking. Get the Workouts Get the Workouts Get the Challenge Get the Workouts Get the Challenge Get the Challenge Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Workouts Get the Challenge Get the Workouts You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Epoch Times
an hour ago
- Epoch Times
Why You Wake Up With a Bitter Taste–and How to Fix It Naturally
Waking up with a bitter taste in your mouth—or noticing it after meals—may seem minor. However, in traditional Chinese medicine (TCM), it could signal deeper imbalances. From liver and gallbladder dysfunction to emotional stress and poor digestion, TCM offers a holistic view of this puzzling symptom and practical remedies to restore harmony. The Root Causes of Bitter Taste in TCM According to TCM, bitterness in the mouth is frequently associated with issues concerning the liver and gallbladder. Dr. Yang Jingduan, a board-certified psychiatrist and a fifth-generation practitioner of TCM, shared a case in an interview with The Epoch Times. A 40-year-old man experienced a bitter taste in his mouth every morning. After examination, his liver function was found to be slightly abnormal, and a gallbladder ultrasound revealed bile congestion.
Yahoo
2 hours ago
- Yahoo
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment which was approved by the U.S. Food and Drug Administration (FDA) in 2023. 'This is an important milestone for maternal health in the European Union,' said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. 'ZURZUVAE represents a novel therapeutic approach for the targeted treatment of postpartum depression, with data demonstrating potential for symptom improvement as early as day three of a 14-day course. If approved, this represents a significant opportunity to advance the treatment of a serious condition that remains both underdiagnosed and undertreated.' PPD is one of the most common medical conditions associated with pregnancy.1-3 Symptoms of PPD may include depressed mood, anxiety, affected ability to bond with the newborn, functional impairment of daily activities, feelings of guilt and worthlessness, doubts about motherhood, and thoughts of self- or infant harm.1 Left untreated, PPD symptoms may persist beyond the postpartum period and can lead to prolonged maternal morbidities and repercussions on child development.4-6 In Europe, an estimated 5-20% of women with a pregnancy experience symptoms of PPD.7-12 Because clinical guidelines for screening and management of depression during and after pregnancy vary across European countries, many cases may go undiagnosed and untreated.3 Death by suicide during the perinatal period is a leading cause of maternal mortality in Europe.4, 13 The CHMP's recommendation for ZURZUVAE is based on the SKYLARK Study evaluating ZURZUVAE which met its primary endpoint, a significant mean reduction from baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score, a common measure of depression severity, at Day 15 as compared to placebo. All key secondary endpoints were also met, with significant reduction in depressive symptoms seen as early as Day 3 and sustained through Day 45 compared to placebo. ZURZUVAE was generally well-tolerated. The most frequently reported side effects ≥ 5% and greater than placebo in patients treated with ZURZUVAE 50 mg were somnolence, dizziness, and sedation. The CHMP's recommendation for ZURZUVAE will now be reviewed by the EC for marketing authorization in the European Union with a final decision expected in the third quarter of 2025. The U.S. FDA approved ZURZUVAE in August 2023 and the Drug Enforcement Agency (DEA) scheduled it as a Class IV controlled substance on October 31, 2023. About ZURZUVAE® (zuranolone)In the U.S., ZURZUVAE® is a once-daily, oral, 14-day medicine for treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes to regulating brain function. ZURZUVAE was discovered by Sage Therapeutics, Inc. (Nasdaq: SAGE), and in 2020 Biogen and Sage Therapeutics entered into a collaboration to jointly develop and commercialize ZURZUVAE in the U.S. As part of the agreement, Biogen received exclusive rights to develop and commercialize ZURZUVAE outside of the U.S., excluding Japan, Taiwan and South Korea. About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at Follow us on social media - Facebook, LinkedIn, X, YouTube. Biogen Safe Harbor This news release contains forward-looking statements, including relating to; the potential, benefits, safety and efficacy of zuranolone (marketed under the brand name ZURZUVAE); the potential of Biogen's commercial business and pipeline programs, including ZURZUVAE; the anticipated benefits and potential of Biogen's collaboration arrangement with Sage; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'guidance,' 'hope,' 'intend,' 'may,' 'objective,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'prospect,' 'should,' 'target,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned 'Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise. References: American Psychiatric Association, Diagnostic and statistical manual of mental disorders (5th ed.). 5 ed. 2013, Washington, DC. Vigod, S.N., et al., Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders: Guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l'humeur, des troubles anxieux et des troubles connexes perinatals. Can J Psychiatry, 2025: p. 7067437241303031. Motrico, E., et al., Clinical practice guidelines with recommendations for peripartum depression: A European systematic review. Acta Psychiatr Scand, 2022. 146(4): p. 325-339. The Lancet Regional, H.-E., Support not stigma: redefining perinatal mental health care. Lancet Reg Health Eur, 2024. 40: p. 100930. Slomian, J., et al., Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. Womens Health (Lond), 2019. 15: p. 1745506519844044. Rogers, A., et al., Association Between Maternal Perinatal Depression and Anxiety and Child and Adolescent Development: A Meta-analysis. JAMA Pediatr, 2020. 174(11): p. 1082-1092. Clavenna, A., et al., Postnatal depression screening in a paediatric primary care setting in Italy. BMC Psychiatry, 2017. 17(1): p. 42. Cena, L., et al., Prevalence of maternal antenatal and postnatal depression and their association with sociodemographic and socioeconomic factors: A multicentre study in Italy. J Affect Disord, 2021. 279: p. 217-221. Della Corte, L., et al., Prevalence and associated psychological risk factors of postpartum depression: a cross-sectional study. J Obstet Gynaecol, 2022. 42(5): p. 976-980. Pataky, E.A. and U. Ehlert, Longitudinal assessment of symptoms of postpartum mood disorder in women with and without a history of depression. Arch Womens Ment Health, 2020. 23(3): p. 391-399. Dekel, S., et al., The dynamic course of peripartum depression across pregnancy and childbirth. J Psychiatr Res, 2019. 113: p. 72-78. Holm, D.L., et al., A quantitative comparison of two measures of postpartum depression. BMC Psychiatry, 2022. 22(1): p. 202. Diguisto, C., et al., Maternal mortality in eight European countries with enhanced surveillance systems: descriptive population based study. BMJ, 2022. 379: p. e070621. MEDIA CONTACT:Allison Murphy+ 1 781 464 INVESTOR CONTACT:Tim Power+1 781 464 2442IR@
